drugset / Trial / NCT04285229
A Study of Ixekizumab (LY2439821) in Chinese Participants With Radiographic Axial Spondyloarthritis
RandomizedParallel-groupDouble-blindTreatment
Summary
The main purpose of this study is to evaluate the efficacy and safety of ixekizumab in Chinese participants with radiographic axial spondyloarthritis (r-axSpA).
Timeline
- Start
- 2020-04-10
- Primary completion
- 2021-03-31
- Completion
- 2022-03-17
Publications
- Sengupta R, Machado PM, Goupille P, Rudwaleit M, Sheesh M, Ng KJ, Ngantcha M, Yan Y, Russ H, Doridot G, Xue Y, Poddubnyy D, Baraliakos X, Navarro-Compan V. Efficacy of Ixekizumab in Radiographic Axial Spondyloarthritis by Baseline C-Reactive Protein Level: A Pooled Analysis of Phase III Trials. Rheumatol Ther. 2026 Jun 2. doi: 10.1007/s40744-026-00862-1. Online ahead of print.
- Zhu X, Hu J, Liu D, Li J, Wu H, Sun L, Dai L, Tan C, Li Z, Xiao Z, Wang Y, Dong L, Yan Y, Li H, Zou H. Efficacy of Ixekizumab in Chinese Patients with Radiographic-Axial Spondyloarthritis by Baseline Inflammation Status on Magnetic Resonance Imaging. Rheumatol Ther. 2026 Apr;13(2):313-327. doi: 10.1007/s40744-025-00819-w. Epub 2026 Jan 6.
- Kong N, Hu J, Liu D, Li J, Wu H, Sun L, Lie D, Tan C, Li Z, Xiao Z, Huang C, Xu J, Yan Y, Li H, Zou H. Efficacy of Ixekizumab in Chinese Patients with Radiographic Axial Spondyloarthritis by Baseline C-Reactive Protein Level. Rheumatol Ther. 2025 Aug;12(4):627-639. doi: 10.1007/s40744-025-00765-7. Epub 2025 May 9.
- Zhu X, Hu J, Liu D, Li J, Wu H, Sun L, Dai L, Tan C, Li Z, Xiao Z, Li X, Yan Y, Dou G, Sun Y, Zou H. Rapid and Sustained Effect of Ixekizumab on Patient Global, Spinal Pain, Stiffness, and Fatigue in Chinese Patients with Radiographic Axial Spondyloarthritis. Rheumatol Ther. 2024 Aug;11(4):1011-1022. doi: 10.1007/s40744-024-00688-9. Epub 2024 Jun 21.
- Xue Y, Hu J, Liu D, Li J, Wu H, Tan C, Dai L, Sun L, Li Z, Xiao Z, Huang C, Yan Y, Ji F, Chen R, Zou H. Ixekizumab for Active Radiographic Axial Spondyloarthritis in Chinese Patients: 16- and 52-Week Results from a Phase III, Randomized, Double-Blind, Placebo-Controlled Study. BioDrugs. 2024 Jan;38(1):145-156. doi: 10.1007/s40259-023-00625-2. Epub 2023 Sep 22.
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Ixekizumab | Monoclonal antibody | 80 mg | Subcutaneous |